Table 1.
Patient Characteristics and COVID-19 Vaccine Hypersensitivity
| Characteristic | Value |
|---|---|
| Age, mean (SD), y | 56 (16) |
| Sex, n (%) | |
| Female | 34 (87) |
| Male | 5 (13) |
| Ethnicity, n (%) | |
| White | 34 (87) |
| African American | 3 (8) |
| Hispanic | 2 (5) |
| Vaccine, n (%) | |
| Moderna | 19 (47.5) |
| Pfizer | 19 (47.5) |
| Janssen | 2 (5)a |
| Patients on baseline antihistamine, n (%) | 14 (36) |
| Patients on baseline montelukast, n (%) | 8 (21) |
| Peripheral eosinophilia, n (%) | 3 (8) |
| Elevated serum tryptase, n (%) | 2 (5) |
| Atopic, n (%) | 37 (95) |
| Concomitant allergic disorders, n (%)b | |
| Allergic rhinitis | 21 (54) |
| Antibiotics allergy | 21 (54) |
| Asthma or COPD | 12 (31) |
| Food allergy | 8 (21) |
| Chronic idiopathic urticaria and angioedema | 16 (41) |
| Mastocytosis | 1 (3) |
| Most common reactions, n (%) | |
| Immediate urticaria and angioedema (<4 h after vaccine) | 14 (36) |
| Delayed urticaria and angioedema (>4 h after vaccine) | 11 (28) |
| Asthma, COPD chest tightness, or shortness of breath | 3 (8) |
| Syncopal or vasovagal | 2 (5) |
| Concerning high-risk history for potential to have allergic reaction on receipt of vaccine | |
| Allergy to meds or other high-risk allergy history (includes latex and hymenoptera) | 5 (13) |
| Reaction to other vaccines or injectables | 6 (15)c |
| Clinical history of concern for polyethylene glycol allergy | 2 (5) |
| Treatments of acute vaccine reactions requiring intramuscular epinephrine and systemic corticosteroids | |
| Received intramuscular epinephrine and systemic corticosteroids, n (%) | 2 (5) |
| Received systemic corticosteroids only, n (%) | 2 (5) |
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; meds, medications.
a
A total of 40 vaccines, 39 patients (1 received Moderna and then Janssen).
b
Total percentages exceeded 100% owing to overlap.
c
4 patients had reaction to influenza vaccine. 2 patients had reaction to omalizumab.